Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Gilbertson

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Blood Neoplasia|November 24, 2025
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FLRachel M Koldej, Allison Barraclough, Huw Morgan, et al.
Blood Advances|March 31, 2022
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphomaAnas Younes, John M Burke, Catherine Diefenbach, et al.
British Journal of Haematology|March 3, 2023
Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma AllianceKenneth J C Lim, Pietro Di Ciaccio, Mark N Polizzotto, et al.
Blood Advances|January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR studyAllison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
British Journal of Haematology|March 13, 2018
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphomaJorge J Castillo, Thomas Guerrero-Garcia, Francesco Baldini, et al.
Biochemical Pharmacology|April 8, 2022
Obesity I: Overview and molecular and biochemical mechanismsRobert H Lustig, David Collier, Christopher Kassotis, et al.
Blood Advances|April 9, 2024
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancyZoe K McQuilten, Robert Weinkove, Le Thi Phuong Thao, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Blood Advances|March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignanciesSara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Blood Neoplasia|November 24, 2025
T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FLRachel M Koldej, Allison Barraclough, Huw Morgan, et al.
Blood Advances|March 31, 2022
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphomaAnas Younes, John M Burke, Catherine Diefenbach, et al.
British Journal of Haematology|March 3, 2023
Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma AllianceKenneth J C Lim, Pietro Di Ciaccio, Mark N Polizzotto, et al.
Blood Advances|January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR studyAllison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
British Journal of Haematology|March 13, 2018
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphomaJorge J Castillo, Thomas Guerrero-Garcia, Francesco Baldini, et al.
Biochemical Pharmacology|April 8, 2022
Obesity I: Overview and molecular and biochemical mechanismsRobert H Lustig, David Collier, Christopher Kassotis, et al.
Blood Advances|April 9, 2024
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancyZoe K McQuilten, Robert Weinkove, Le Thi Phuong Thao, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Blood Advances|March 14, 2024
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignanciesSara Carrillo de Albornoz, Alisa M Higgins, Dennis Petrie, et al.
Hematological Oncology|April 16, 2019
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphomaZi Yun Ng, Mark Bishton, David Ritchie, et al.
Pageof 6